-- 週四下午晚些時候，金融股走高，紐約證券交易所金融指數上漲1.3%，道富金融精選行業SPDR ETF（XLF）上漲0.5%。 費城住房指數上漲1.6%，道富房地產精選產業SPDR ETF（XLRE）上漲1.5%。 比特幣（BTC-USD）上漲0.9%至76,409美元，10年期美國公債殖利率下降2.8個基點至4.39%。 企業新聞方面，根據彭博社報道，AvalonBay Communities（AVB）和Equity Residential（EQR）已就潛在的合併事宜展開磋商，這將是有史以來規模最大的房地產交易之一。 AvalonBay股價下跌1.1%，Equity Residential股價小幅下跌。
Related Articles
Mining & Metals
Agnico Eagle Q1 Record Adjusted Net Income of U$1,706 million or $3.41 per share
$AEM.TO
Treasury
TD Bank Group Issues 150 Million Swiss francs Green Bond
Toronto-Dominion Bank (TD.TO) after the close Thursday said it issued its seventh sustainable-labelled bonds for 150-million Swiss francs. The bank said its total sustainable bond issuances have now exceeded C$5.2 billion since 2014."TD's first European green bond continues building the strength of our sustainable financing program, helping us support clients pursuing sustainable investment in a new jurisdiction," said Nicole Vadori, head of sustainability at TD.TD shares closed up $3.40 at $146.33 on Toronto Stock Exchange.
$TD$TD.TO
Research
Research Alert: Amgn Q1 Tops Estimates Driven By Diversified Growth And Pipeline Investments
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.
$AMGN